Monday Apr 30 | BioSpace
Regulus Therapeutics, Inc. Appoints to its Board of Directors
Dr. Carter currently serves as an independent member of the Board of Directors of Immune Design Corp., a privately held biotech company located in , and as a board member of additional scientific organizations.
Bristol-Myers Squibb offers 84-% premium to buy ZymoGenetics for $885 million
US drugmaker Bristol-Myers Squibb, yesterday revealed plans to pay a whopping premium of 84 per cent to acquire biotechnology company ZymoGenetics Inc for $885 million.